MCID: MNN020
MIFTS: 45

Meningococcal Infection

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningococcal Infection

MalaCards integrated aliases for Meningococcal Infection:

Name: Meningococcal Infection 20 17 32
Meningococcal Infections 42 70

Classifications:



External Ids:

ICD10 32 A39 A39.9
UMLS 70 C0025303

Summaries for Meningococcal Infection

MedlinePlus : 42 Meningococci are a type of bacteria that cause serious infections. The most common infection is meningitis, which is an inflammation of the thin tissue that surrounds the brain and spinal cord. Meningococci can also cause other problems, including a serious bloodstream infection called sepsis. Meningococcal infections can spread from person to person. Risk factors include Age - it is more common in infants, teens, and young adults Living in close quarters, such as in college dorms or military settings Certain medical conditions, such as not having a spleen Travel to areas where meningococcal disease is common In its early stages, you may have flu-like symptoms and a stiff neck. But the disease can progress quickly and can be fatal. Early diagnosis and treatment are extremely important. Lab tests on your blood and cerebrospinal fluid can tell if you have it. Treatment is with antibiotics. Since the infection spreads from person to person, family members may also need to be treated. A vaccine can prevent meningococcal infections.

MalaCards based summary : Meningococcal Infection, also known as meningococcal infections, is related to respiratory failure and cerebral palsy, and has symptoms including fever and pruritus. An important gene associated with Meningococcal Infection is ADD1 (Adducin 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Calcium signaling pathway. The drugs Amphotericin B and Phenytoin have been mentioned in the context of this disorder. Affiliated tissues include spleen, spinal cord and brain, and related phenotype is cardiovascular system.

Wikipedia : 73 Neisseria meningitidis, often referred to as meningococcus, is a Gram-negative bacterium that can cause... more...

Related Diseases for Meningococcal Infection

Diseases related to Meningococcal Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 respiratory failure 29.2 TTR SOD1 G6PD ADRB2
2 cerebral palsy 29.2 SOD1 GSR ADRB2 ADD1
3 waterhouse-friderichsen syndrome 11.1
4 properdin deficiency, x-linked 11.1
5 complement factor h deficiency 11.0
6 neisseria meningitidis infection 10.7
7 meningococcal meningitis 10.6
8 meningococcemia 10.5
9 meningitis 10.5
10 toxic shock syndrome 10.3
11 bacterial meningitis 10.3
12 brain edema 10.3
13 resting heart rate, variation in 10.3 ADRB2 ADRB1
14 ocular hypotension 10.3 ADRB2 ADRB1
15 exanthem 10.3
16 disseminated intravascular coagulation 10.3
17 pericarditis 10.3
18 nasopharyngitis 10.2
19 purpura 10.2
20 plantar fascial fibromatosis 10.2 AGTR1 AGT
21 acute mountain sickness 10.2 AGTR1 ADRB2
22 posterior urethral valves 10.2 AGTR1 AGT
23 fibromuscular dysplasia 10.2 AGTR1 AGT
24 septic arthritis 10.2
25 renal artery disease 10.2 AGTR1 AGT
26 malignant secondary hypertension 10.2 AGTR1 AGT
27 familial hypertension 10.2 AGTR1 AGT
28 anuria 10.2 AGTR1 AGT
29 bacterial infectious disease 10.1
30 complement deficiency 10.1
31 trimethoprim allergy 10.1 GSR G6PD
32 hyperaldosteronism, familial, type i 10.1 AGT ADD1
33 lymphosarcoma 10.1 GSR G6PD
34 renal tubular dysgenesis 10.1 AGTR1 AGT
35 malignant hypertension 10.1 AGTR1 AGT
36 orthostatic intolerance 10.1 AGTR1 ADRB2 ADRB1
37 purpura fulminans 10.1
38 meningoencephalitis 10.1
39 myocarditis 10.1
40 haemophilus influenzae 10.1
41 diastolic heart failure 10.1 AGTR1 AGT
42 iga glomerulonephritis 10.0 AGTR1 AGT ADD1
43 diabetic cataract 10.0 GSR G6PD
44 atrial fibrillation 10.0 AGTR1 AGT ADRB1
45 nonarteritic anterior ischemic optic neuropathy 10.0 G6PD AGTR1 AGT
46 ocular motor apraxia 10.0
47 branchiootic syndrome 1 10.0
48 complement component 5 deficiency 10.0
49 complement component 7 deficiency 10.0
50 subdural empyema 10.0

Graphical network of the top 20 diseases related to Meningococcal Infection:



Diseases related to Meningococcal Infection

Symptoms & Phenotypes for Meningococcal Infection

UMLS symptoms related to Meningococcal Infection:


fever; pruritus

MGI Mouse Phenotypes related to Meningococcal Infection:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.32 ADRB1 ADRB2 AGT AGTR1 C7 G6PD

Drugs & Therapeutics for Meningococcal Infection

Drugs for Meningococcal Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
2
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
3
Zidovudine Approved Phase 4 30516-87-1 35370
4
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
5
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
6
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
7
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
8
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12 Amebicides Phase 4
13 Antiparasitic Agents Phase 4
14 Antiprotozoal Agents Phase 4
15 Liposomal amphotericin B Phase 4
16
protease inhibitors Phase 4
17 BB 1101 Phase 4
18 HIV Protease Inhibitors Phase 4
19 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
20 Complement Factor H Phase 4
21 Reverse Transcriptase Inhibitors Phase 4
22 Anti-HIV Agents Phase 4
23 Vitamin B9 Phase 4
24 Folic Acid Antagonists Phase 4
25 Vitamin B Complex Phase 4
26 Dermatologic Agents Phase 4
27 Folate Phase 4
28 Gentamicins Phase 4
29 penicillins Phase 4
30 Lactams Phase 4
31 beta-Lactams Phase 4
32 Neuromuscular Blocking Agents Phase 4
33
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
34
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
35
Lactitol Approved, Investigational Phase 3 585-86-4 157355
36
BCG vaccine Approved, Investigational Phase 3
37
Sulfamethoxazole Approved Phase 3 723-46-6 5329
38
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
39
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
40
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
41
Sertraline Approved Phase 3 79617-96-2 68617
42
Glycerol Approved, Investigational Phase 3 56-81-5 753
43
Isoniazid Approved, Investigational Phase 3 54-85-3 3767
44
Rifampicin Approved Phase 3 13292-46-1 5381226 5458213
45
Linezolid Approved, Investigational Phase 3 165800-03-3 441401
46
Pyrazinamide Approved, Investigational Phase 3 98-96-4 1046
47
Ethambutol Approved Phase 3 74-55-5 3279 14052
48
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
49
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
50
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380

Interventional clinical trials:

(show top 50) (show all 382)
# Name Status NCT ID Phase Drugs
1 Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. A Multi-center Comparative Randomized Double-blind and Placebo-controlled Clinical Trial Unknown status NCT01478035 Phase 4 Phenytoin;placebo
2 A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate® Unknown status NCT00262015 Phase 4
3 Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study) Unknown status NCT03682939 Phase 4
4 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
5 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
6 A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
7 Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure Completed NCT02569632 Phase 4
8 Safety and Immunogenicity of Intradermal, and Low-dose Subcutaneous vs Subcutaneous Administration of Menomune® - A/C/Y/W-135 Completed NCT00850603 Phase 4
9 Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life. Completed NCT00392808 Phase 4
10 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age Completed NCT00310713 Phase 4
11 A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign Completed NCT00310687 Phase 4
12 A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule Completed NCT00316654 Phase 4
13 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age Completed NCT00310700 Phase 4
14 A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age Completed NCT00310635 Phase 4
15 Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine Versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine in Children 2-6 Years of Age in China Completed NCT01430611 Phase 4
16 An Open Label Randomised Controlled Study to Evaluate the Induction of Immune Memory Following Infant Vaccination With a Glycoconjugate Neisseria Meningitidis Serogroup C Vaccine and to Assess the Immunological Impact of Administering Routine Infant Immunisations in Consistent Versus Alternating Limbs Completed NCT01129518 Phase 4
17 South Australian Meningococcal B Vaccine Herd Immunity Study Completed NCT03089086 Phase 4
18 Multicentric, Surveillance Study to Monitor Safety of GSK Biologicals' Purified Meningococcal Polysaccharide Vaccine of Serogroups ACWY in 3,000 Filipino Subjects Aged Above 2 Years When Administered According to the Prescribing Information. Completed NCT00290329 Phase 4
19 A Randomized Clinical Study to Determine the Patient Benefit and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of Neoplastic Meningitis Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
20 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
21 A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age Completed NCT01896596 Phase 4
22 Babies Born Early Antibody Response to Men B Vaccination: A Phase IV Multicentre Randomised Study to Evaluate the Primary and Booster Immune Responses in UK Preterm Infants Receiving Routine Immunisations and Incorporating a Three Dose Versus a Two Dose Schedule of 4CMenB (Bexsero®) for Primary Immunisation. Completed NCT03125616 Phase 4
23 Postmarketing Surveillance Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in the Republic of Korea Completed NCT02864927 Phase 4
24 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response Completed NCT02724046 Phase 4 Ciprofloxacin
25 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
26 Assay of the Immunogenicity of Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine in Africa Completed NCT00271479 Phase 4
27 A Phase IV, Partially Double-blind Study to Demonstrate Non-inferiority of GSK Biologicals' Mencevax™ ACWY (New Process) Versus Mencevax™ ACWY (Current Process) When Administered as a Single Dose to Subjects Aged 2-30 Yrs Completed NCT00227422 Phase 4
28 A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine Completed NCT01823536 Phase 4
29 An Open Randomised Trial of Ceftriaxone v Penicillin and Gentamicin in Infant Severe Sepsis and Bacterial Meningitis in Malawi Completed NCT01247909 Phase 4 Ceftriaxone v penicillin and gentamicin
30 Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines Completed NCT00197808 Phase 4
31 A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ACWY Conjugate Vaccine(MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects From 2 Months to 55 Years of Age in the Republic of South Korea. Completed NCT01766206 Phase 4
32 A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis Completed NCT00976040 Phase 4
33 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
34 Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
35 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
36 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
37 A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the GSK MenACWY Conjugate Vaccine at 2, 4, 6 and 12 Months of Age in South Korea Completed NCT02446691 Phase 4
38 Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections. Completed NCT01745679 Phase 4 Ceftriaxone treatment
39 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
40 Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis, Especially of Pneumococcal Meningitis, in Angola. Completed NCT01540838 Phase 4 Infusion with paracetamol;Bolus without paracetamol
41 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
42 Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines Completed NCT01270503 Phase 4
43 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier Completed NCT02633787 Phase 4
44 A Phase IV Randomized, Observer-blind, Controlled Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine as Compared to Sanofi Pasteur Menactra® Vaccine in Healthy Subjects Aged 2-10 Years Recruiting NCT04450498 Phase 4
45 A Randomized, Controlled Trial to Compare Protection in Adolescents Between Different Meningococcal Immunization Schedules Used in Canada; a Canadian Immunization Research Network (CIRN) Study. Active, not recruiting NCT03694405 Phase 4
46 Mild Induced Hypothermia to Treat Severe Community Acquired Meningitis in Adults Admitted to Intensive Care Unit Terminated NCT00774631 Phase 4
47 Amikacin Penetration Into the Cerebrospinal Fluid: Pharmacokinetic/Pharmacodynamic Analysis in Adults With Hospital Acquired Gram-negative Meningitis Associated With Intracranial Pressure Monitoring and Draining Devices Withdrawn NCT00362245 Phase 4 Systemic and Intra-Thecal Amikacin Therapy
48 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin Prophylaxis as a Response to a Meningococcal Meningitis Epidemic Withdrawn NCT03431675 Phase 4 Ciprofloxacin
49 Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Sub-Saharan Africa Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Complemented by Repeat Lumbar Punctures Unknown status NCT01715922 Phase 2, Phase 3 Fluconazole;Flucytosine
50 A Phase 3, Multi-center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine Completed NCT00450437 Phase 3

Search NIH Clinical Center for Meningococcal Infection

Genetic Tests for Meningococcal Infection

Anatomical Context for Meningococcal Infection

MalaCards organs/tissues related to Meningococcal Infection:

40
Spleen, Spinal Cord, Brain, Endothelial, Bone Marrow, Bone, Liver

Publications for Meningococcal Infection

Articles related to Meningococcal Infection:

(show top 50) (show all 1543)
# Title Authors PMID Year
1
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. 42
33417592 2020
2
Genomic analysis of the meningococcal ST-4821 complex-Western clade, potential sexual transmission and predicted antibiotic susceptibility and vaccine coverage. 42
33301524 2020
3
Genomic surveillance of Neisseria meningitidis serogroup B invasive strains: Diversity of vaccine antigen types, Brazil, 2016-2018. 42
33347452 2020
4
Recent advances in the treatment of neuromyelitis optica spectrum disorders. 61
33741809 2021
5
Validating clinical practice guidelines for the management of children with non-blanching rashes in the UK (PiC): a prospective, multicentre cohort study. 61
33186517 2021
6
The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. 61
33048203 2021
7
Intranasal immunization with a rNMB0315 and combination adjuvants induces protective immunity against Neisseria meningitidis serogroup B in mice. 61
33548582 2021
8
Interventions for atypical haemolytic uraemic syndrome. 61
33783815 2021
9
Modulation of Human Beta-Defensin 2 Expression by Pathogenic Neisseria meningitidis and Commensal Lactobacilli. 61
33468461 2021
10
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. 61
33586143 2021
11
Safety of current treatments for paroxysmal nocturnal hemoglobinuria. 61
33249943 2021
12
Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. 61
33407224 2021
13
Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance. 61
33796147 2021
14
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. 61
33307104 2020
15
Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs. 61
33275746 2020
16
Lung abscess due to Neisseria meningitidis serogroup X-unexpected virulence of a commensal resulting from putative serogroup B capsular switching. 61
32666483 2020
17
Meningococcal infections among refugees and immigrants: silent threats of past, present and future. 61
32347773 2020
18
A severe course of serogroup W meningococcemia in a patient with infantile nephropathic cystinosis. 61
32401678 2020
19
Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial. 61
33213529 2020
20
The legacy of MeNZB and possible implications for COVID-19 vaccination. 61
33223554 2020
21
Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients. 61
32869125 2020
22
Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016. 61
32747215 2020
23
Evidence for Multi-Organ Infection During Experimental Meningococcal Sepsis due to ST-11 Isolates in Human Transferrin-Transgenic Mice. 61
32977487 2020
24
A Syrian refugee with meningococcal empyema. 61
31922922 2020
25
Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients. 61
32766853 2020
26
Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases. 61
32240525 2020
27
Meningococcal Infections in Children and Adolescents: Update and Prevention. 61
32591062 2020
28
Surveillance of penicillin resistance of Neisseria meningitidis strains from invasive infections between 2013 and 2018 in Turkey. 61
32028863 2020
29
Recurrent invasive meningococcal infections - quantifying the risk, Germany, 2002 to 2018. 61
32613936 2020
30
[A new type of active matter explains the mechanism of bacterial aggregation and its impact on meningococcal infection]. 61
32720484 2020
31
Human genetics of meningococcal infections. 61
32067109 2020
32
Recurrent meningococcal meningitis with complement 6 (C6) deficiency: A case report. 61
32481330 2020
33
Disseminated meningococcal infection, early petechiae. 61
32045696 2020
34
Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome. 61
32159209 2020
35
Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. 61
29992261 2020
36
Genetic incorporation of non-canonical amino acid photocrosslinkers in Neisseria meningitidis: New method provides insights into the physiological function of the function-unknown NMB1345 protein. 61
32866169 2020
37
Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database. 61
33204170 2020
38
[Meningococcemia: Different Serotypes in the Same Region]. 61
32050887 2020
39
Disseminated Gonococcal Infection Associated with Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria: A Case Report and Literature Review. 61
32765045 2020
40
Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces. 61
31787413 2020
41
Prevention of Opportunistic Infections in Women With HIV Infection. 61
31433312 2019
42
Combined vaccines for prophylaxis of infectious conditions. 61
30829068 2019
43
Atypical, Yet Not Infrequent, Infections with Neisseria Species. 61
31861867 2019
44
Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections. 61
31274379 2019
45
The meningococcal vaccine antigen GNA2091 is an analogue of YraP and plays key roles in outer membrane stability and virulence. 61
31442078 2019
46
Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. 61
31890998 2019
47
Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. 61
31421540 2019
48
Purpuric rash and fever among hospitalized children aged 0-18 years: Comparison between clinical, laboratory, therapeutic and outcome features of patients with bacterial versus viral etiology. 61
30922715 2019
49
Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential. 61
32335565 2019
50
Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines. 61
31671447 2019

Variations for Meningococcal Infection

Expression for Meningococcal Infection

Search GEO for disease gene expression data for Meningococcal Infection.

Pathways for Meningococcal Infection

Pathways related to Meningococcal Infection according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.48 TTR GSR AGTR1 AGT
2 12.03 AGTR1 ADRB2 ADRB1
3
Show member pathways
12 ADRB2 ADRB1 ADD1
4 11.99 SOD1 AGT ADRB2 ADRB1
5
Show member pathways
11.76 AGTR1 AGT ADRB2 ADRB1
6 10.96 AGTR1 ADRB2
7 10.86 SOD1 GSR
8 10.76 AGTR1 AGT ADRB2 ADRB1
9 10.68 ADRB2 ADRB1
10 10.51 GSR G6PD

GO Terms for Meningococcal Infection

Cellular components related to Meningococcal Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.17 TTR SOD1 GSR G6PD CPB2 C7

Biological processes related to Meningococcal Infection according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cellular response to oxidative stress GO:0034599 9.69 SOD1 GSR G6PD
2 activation of adenylate cyclase activity GO:0007190 9.63 ADRB2 ADRB1
3 response to cold GO:0009409 9.62 ADRB2 ADRB1
4 positive regulation of catalytic activity GO:0043085 9.62 SOD1 AGT
5 positive regulation of reactive oxygen species metabolic process GO:2000379 9.61 AGTR1 AGT
6 brown fat cell differentiation GO:0050873 9.61 ADRB2 ADRB1
7 regulation of blood vessel diameter GO:0097746 9.6 AGTR1 ADRB2
8 regulation of vasoconstriction GO:0019229 9.59 AGTR1 AGT
9 cellular sodium ion homeostasis GO:0006883 9.58 C7 AGT
10 positive regulation of superoxide anion generation GO:0032930 9.58 SOD1 AGT
11 glutathione metabolic process GO:0006749 9.58 SOD1 GSR G6PD
12 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.57 AGTR1 AGT
13 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.56 ADRB2 ADRB1
14 low-density lipoprotein particle remodeling GO:0034374 9.55 AGTR1 AGT
15 positive regulation of cellular protein metabolic process GO:0032270 9.54 AGTR1 AGT
16 diet induced thermogenesis GO:0002024 9.52 ADRB2 ADRB1
17 negative regulation of multicellular organism growth GO:0040015 9.49 ADRB2 ADRB1
18 positive regulation of cholesterol esterification GO:0010873 9.48 AGTR1 AGT
19 positive regulation of NAD(P)H oxidase activity GO:0033864 9.46 AGTR1 AGT
20 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.43 AGTR1 AGT
21 regulation of renal sodium excretion GO:0035813 9.37 AGTR1 AGT
22 positive regulation of extracellular matrix constituent secretion GO:0003331 9.32 CPB2 AGT
23 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.26 ADRB2 ADRB1
24 renin-angiotensin regulation of aldosterone production GO:0002018 9.16 AGTR1 AGT
25 regulation of blood vessel diameter by renin-angiotensin GO:0002034 8.96 AGTR1 AGT
26 heat generation GO:0031649 8.62 ADRB2 ADRB1

Molecular functions related to Meningococcal Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADP binding GO:0050661 8.96 GSR G6PD
2 adrenergic receptor activity GO:0004935 8.62 ADRB2 ADRB1

Sources for Meningococcal Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....